Surrozen, Inc. (NasdaqCM: SRZN)
Health Care · Biotechnology · US
$24.76
-16.60% today · +114.8% 1Y
Surrozen, Inc. (NasdaqCM: SRZN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $348.96M and employs 44 people.
Over the last twelve months the share price has gained 114.8%, trading between 11.39 and 37.83.
Tweenvest scores Surrozen, Inc. across four factors: quality 32/100, value 61/100. Its strongest factor is value.
SRZN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $348.96M
- Revenue (TTM)
- $11.51M
- P/E
- —
- EPS
- -32.19
- Dividend yield
- —
- Beta (5Y)
- 0.47
- 52-week high
- $37.83
- 52-week low
- $11.39
- Avg volume (3M)
- —
- Shares outstanding
- 11.75M
- Employees
- 44
- Next earnings
- —
About Surrozen, Inc.
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
- ISIN
- US86889P2083
- Founded
- 2015
- Listed since
- Jan 11, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Cuorips Inc.TSE: 4894 | $353.89M | ¥6,310.00 | +0.80% |
| Jiangsu CoWin Biotech Co., Ltd.SHSE: 688426 | $353.03M | CN¥21.51 | -4.74% |
| Jiangsu Gdk Biological Technology Co., LtdSHSE: 688670 | $352.60M | CN¥19.17 | +2.35% |
| BioDlink International Company LimitedSEHK: 1875 | $350.57M | HK$3.56 | -4.30% |
| BioNote, Inc.KOSE: A377740 | $348.29M | ₩4,640.00 | -1.28% |
| Jiangsu Recbio Technology Co., Ltd.SEHK: 2179 | $347.01M | HK$4.42 | +0.23% |
| ROKIT Healthcare Inc.KOSDAQ: A376900 | $346.80M | ₩26,850.00 | -3.24% |
| Agenus Inc.NasdaqCM: AGEN | $334.50M | $7.43 | -3.13% |
Figures last refreshed Oct 11, 2026.